{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-031572","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.866213+00:00","generated_at":"2026-05-17T02:30:32.297524+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference","bullets":["Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.","QO mediated TUSC2 overexpression induced apoptosis in ALK+ cell lines and patient-derived organoids.","Combination treatment showed reduced tumor regrowth 2 weeks after end of dosing vs single agents.","Data support potential clinical trial of Reqorsa for ALK-EML4 positive NSCLC patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-031572","json":"https://secwatch.observer/filing/0001437749-25-031572.json","markdown":"https://secwatch.observer/filing/0001437749-25-031572.md","text":"https://secwatch.observer/filing/0001437749-25-031572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/0001437749-25-031572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/gnpx20251021d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:30:32.297524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}